|Systematic (IUPAC) name|
Minor involvement of CYP2D6 and CYP2A6
|(what is this?)|
Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.
Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.
It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.
- Murdoch D, McTavish D (1991). "Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders". Drugs 42 (2): 240–260. doi:10.2165/00003495-199142020-00006. PMID 1717223.
- BioSpectrum Bureau 1 November 2012 Sinhuan's generic heart drug gets production approval
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|